Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $1.96M fell 61.2% year over year. Sequentially, it rose 114.9% from the prior quarter.
Context
- Operating expenses increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 7.82M USD
- Year-over-year change
- +79.7%
- 2-year CAGR
- +43.8%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.82M | +79.7% |
| FY2024 | 2024-12-31 | 4.35M | +15.1% |
| FY2023 | 2023-12-31 | 3.78M | — |
Operating Expenses vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's LTM Mar 2026 operating expenses of $4.73M is the lowest of the 8 companies compared; the peer median is $87.05M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $189.56M | -47.4% | -10.9% | 611487.1% | |
| LTM Mar 2026 | $175.02M | +230.2% | +51.0% | 1472.9% | |
| LTM Mar 2026 | $133.59M | +162.6% | +28.8% | — | |
| LTM Mar 2026 | $87.05M | -28.0% | -7.0% | 308.4% | |
| LTM Mar 2026 | $56.71M | +659.0% | +158.1% | 204.7% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $47.61M | -33.8% | +48.8% | — |
| LTM Mar 2026 | $37.12M | -25.8% | -3.3% | — | |
PLYXPolaryx Therapeutics, Inc. Common Stock | LTM Mar 2026 | $4.73M | — | — | — |
| Peer median (excluding PLYX) | $87.05M | -25.8% | +28.8% | 890.6% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 2.77M | 2.81M | 6.27M |
| Selling, General & Admin | 1.01M | 1.54M | 1.56M |
| Operating Expenses | 3.78M | 4.35M | 7.82M |
| Depreciation & Amortization | 0 | 0 | 0 |
| EBITDA | (3.78M) | (30.36M) | (8.99M) |
| EBITDA Margin | — | — | — |
| Operating Income | (3.78M) | (4.35M) | (7.82M) |
| Operating Margin | — | — | — |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2K | (26M) | (1.16M) |
| Income Before Tax | (3.78M) | (30.36M) | (8.99M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.02) | (0.16) | (0.19) |
| EPS (Diluted) | (0.02) | (0.16) | (0.19) |
| Weighted Avg Shares | 189.37M | 189.37M | 47.34M |
| Weighted Avg Shares (Diluted) | 189.37M | 189.37M | 47.34M |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.